CVS Will Retain $300M In Drug Rebates In 2018, PBM Says
Executive Summary
CEO Merlo downplays importance of rebates to the firm’s financials as he rebuts accusations that PBMs cause high list prices for drugs.
You may also be interested in...
CVS ‘Guaranteed Net Cost’ Program Is Alternative To High Price/High Rebate Model
Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.
Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects
Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.